Key takeaways
- “Wolverine” is a seller name for a pre-mixed vial of BPC-157 and TB-500, not a compound. Australia’s TGA listed “the Wolverine Stack (combination of BPC-157 and TB-500)” among products it seized in New South Wales (media release, 17 August 2026).
- We found no controlled study of the two together in people (PubMed and ClinicalTrials.gov, 18 Nov 2026). Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 rat study, a 2026 report of three patients who also received other agents, and a 2021 chart review of 16 patients, four of whom also received thymosin β4. Neither human report had a control group.
- Each ingredient has its own evidence: mostly animal studies and small, mostly uncontrolled human studies for BPC-157; animal and cell studies for TB-500, with one placebo-controlled trial recruiting.
- In November 2026 the TGA found no detectable TB-500 in a BPC-157 and TB-500 product from one brand, identified in a New South Wales police investigation, although its label listed it. The TGA did not call that product Wolverine.
- HHS’s October 2026 compounding policy, a draft that is not binding and not an approval, applies only to products with a single active ingredient; HHS says that makes it easier to attribute adverse events to one substance.
01BPC-157, TB-500 and “Wolverine” compared
Two compounds and the mix that contains both, dated 18 November 2026.
| Question | BPC-157 | TB-500 | “Wolverine” |
|---|---|---|---|
| What it is | A synthetic 15-amino-acid peptide | In FDA and HHS documents, a synthetic seven-amino-acid fragment of the protein thymosin β4 | A seller name for one vial mixing BPC-157 and TB-500 |
| Studied as a mix | Not a mix | Not a mix | No study of the mix as sold; two 2026 papers gave both peptides (below) |
| Main evidence | Mostly animal studies (T3) | Animal and cell studies (T3, T4) | None for the mix as sold |
| Human data | Small studies, most without a control group (T2); no peer-reviewed randomised trial published | FDA found no articles in which TB-500 was given to people; a 2026 report describes three patients given it with other agents, without a control group; one placebo-controlled trial is recruiting | No controlled study of the two together in people found |
| What a lab report must confirm | One identity and one amount | One identity and one amount | Two identities and two amounts in one vial |
| United States, Nov 2026 | Not approved; FDA staff recommended against 503A listing, and the advisory committee voted for it (Jul 2026) | Not approved; FDA staff recommended against 503A listing, and the advisory committee voted for it (Jul 2026) | HHS’s interim compounding policy requires a single active ingredient |
| Australia (TGA) | Prescription-only medicine | Prescription-only medicine | TGA lab, Nov 2026: no TB-500 detected in one brand’s BPC-157 and TB-500 product, which the TGA did not call Wolverine |
| WADA | Prohibited at all times, class S0 (named) | Prohibited at all times, class S2.3 (named) | Both ingredients are named on the List |
Each ingredient has its own page: BPC-157 and TB-500. The two side by side: BPC-157 vs TB-500.
02What is the “Wolverine peptide”?
“Wolverine” is a product name, not a molecule. Sellers use it for a single vial that holds two peptides, BPC-157 and TB-500. The amount of each is set by whoever fills the vial.
The name is on public record. In a media release of 17 August 2026 about products it seized in New South Wales, Australia’s regulator, the TGA, listed “the Wolverine Stack (combination of BPC-157 and TB-500)”. FDA’s 2026 review of BPC-157 also found websites marketing the two peptides combined in one product, including one that described its products as for research purposes only.
The two ingredients are different molecules:
- BPC-157: a synthetic 15-amino-acid peptide, which FDA staff describe as reported to be a fragment of a protein found in gastric juice.
- TB-500: in FDA’s 2026 review, a synthetic seven-amino-acid fragment (positions 17 to 23) of the 43-amino-acid protein thymosin β4. FDA staff write that thymosin β4 and TB-500 “are not the same substance”: see TB-500 vs thymosin beta-4.
03What studies gave BPC-157 and TB-500 together?
Three papers, one of them with thymosin β4 rather than TB-500. None is a controlled study in people, and none tested a vial sold under a name.
On 21 November 2026 a PubMed search for papers naming BPC-157 together with TB-500 or thymosin beta returned 17 results. Three gave BPC-157 with TB-500 or thymosin β4 to animals or people; none of the other 14 did. ClinicalTrials.gov lists no trial that gives both, and we found no controlled study of the two together in people.
Rats, 2026 (T3). A study from Istanbul cut and repaired the Achilles tendon in 32 rats and randomly assigned eight each to no peptide, BPC-157, TB-500, or both. At four weeks the researchers measured tendon strength and scored the tissue under the microscope. The authors call the study exploratory. Human data on this is lacking, and a study of two peptides given to rats is not a study of a pre-mixed vial.
People (T2, uncontrolled). A 2026 report describes three patients given BPC-157 and TB-500 together with other agents, without a control group. Its authors write that causality “cannot be established”.
People, 2021 (T2, uncontrolled). A retrospective chart review from one US clinic describes 16 patients with knee pain who were given BPC-157; four of them also received thymosin β4. There was no control group. FDA staff write that thymosin β4 and TB-500 “are not the same substance”.
Evidence attaches to what was studied. Whether the two peptides stay intact together in one vial, how much of each is present, and what the mix does are separate questions, and none of the papers we found measured them. The general case is on peptide blends: one vial, no shared evidence.
04What has each ingredient been studied in?
Each row is graded on its own. None of it transfers to a mixed vial.
| Ingredient | Main evidence | In people |
|---|---|---|
| BPC-157 | Mostly animal studies (T3) | Small studies, most without a control group (T2); no peer-reviewed randomised trial published (PubMed, 18 Nov 2026). |
| TB-500 | Animal and cell studies (T3, T4). The best-known mouse study used an unacetylated version, which FDA staff say “cannot be directly extrapolated” to TB-500. | FDA staff found no articles in which TB-500 was given to people. A 2026 report describes three patients given it with BPC-157 and other agents, without a control group (above). One placebo-controlled trial, NCT07487363, began recruiting in February 2026 and has no results. |
Full profiles: the BPC-157 research guide and the TB-500 research guide. Every study we found that gave BPC-157 to people, with its design: BPC-157 human studies.
05Why is a two-peptide vial harder to check and to trace?
Testing. A lab report for one peptide confirms one identity and one amount. A vial with two needs each peptide identified and measured on its own, matched to the batch number. A single purity figure for the whole vial cannot show that both peptides are there, or how much of each. How to read one: how to read a COA.
What a regulator found. Australia’s TGA laboratory reported “No TB-500 detected” in a BPC-157 and TB-500 product from one brand, identified in a New South Wales police investigation, although its label listed TB-500 (advisory of 5 November 2026). The TGA’s conclusion: consumers cannot rely on these labels to know what substance, or what amount, a product contains. The TGA also warns that unapproved peptides “can cause serious health problems including liver damage, severe allergic reactions, inflammation and other health complications requiring medical attention” (media release, 17 August 2026).
Tracing a reaction. FDA’s 2026 review of BPC-157 lists three adverse-event reports from its database. One describes darkening of the skin and gums in a woman using a product labelled for research purposes that contained BPC-157 and TB-500; the reaction returned when she used it again. FDA staff judged that reaction “likely due to the drug product” but, because the product contained two peptides, could not assess whether BPC-157 played a role. Of all three reports, FDA wrote that “it is unclear whether these AEs were attributable to BPC-157”. FDA’s TB-500 review found two complaint reports about “blended TB-500 and BPC-157”, without safety assessments. None of this gives a rate: FDA notes there is no certainty that a reported event was due to the product, and that it does not receive every report. More: BPC-157 side effects.
Compounding. HHS’s interim policy of October 2026 on compounding six peptides, which is not an approval, applies only when the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. HHS gives the reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance.” BPC-157 and TB-500 are both on that list. The Federal Register notice calls the policy a draft that “is not binding”. Background: the HHS peptide policy.
06What we don’t know
- Any effect of BPC-157 and TB-500 together in people. We found no controlled study.
- Whether the two peptides stay intact together in one vial, or change one another. We found no published data.
- Long-term safety of either peptide in people. FDA staff described the human studies of BPC-157 as of short duration with small samples, concluded that potential safety risks of TB-500 in humans are unknown, and wrote that each, given by injection, “may pose a significant risk for immunogenicity”.
- What a given vial contains. A lab report shows only what the tested sample from that lot held, and only for the peptides it identifies and measures.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.